ATE256131T1 - Calanolide zur hemmung von btk - Google Patents
Calanolide zur hemmung von btkInfo
- Publication number
- ATE256131T1 ATE256131T1 AT00916367T AT00916367T ATE256131T1 AT E256131 T1 ATE256131 T1 AT E256131T1 AT 00916367 T AT00916367 T AT 00916367T AT 00916367 T AT00916367 T AT 00916367T AT E256131 T1 ATE256131 T1 AT E256131T1
- Authority
- AT
- Austria
- Prior art keywords
- calanolides
- inhibiting btk
- calanolide
- tec family
- btk inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12603999P | 1999-03-19 | 1999-03-19 | |
US09/354,550 US6306897B1 (en) | 1999-03-19 | 1999-07-15 | Calanolides for inhibiting BTK |
PCT/US2000/006805 WO2000056737A2 (en) | 1999-03-19 | 2000-03-16 | Calanolides for inhibiting btk |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE256131T1 true ATE256131T1 (de) | 2003-12-15 |
Family
ID=26824213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00916367T ATE256131T1 (de) | 1999-03-19 | 2000-03-16 | Calanolide zur hemmung von btk |
Country Status (8)
Country | Link |
---|---|
US (1) | US6306897B1 (de) |
EP (1) | EP1163243B1 (de) |
JP (1) | JP2003528801A (de) |
AT (1) | ATE256131T1 (de) |
AU (1) | AU3748000A (de) |
CA (1) | CA2365244A1 (de) |
DE (1) | DE60007095T2 (de) |
WO (1) | WO2000056737A2 (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003516351A (ja) * | 1999-11-30 | 2003-05-13 | パーカー ヒューズ インスティテュート | コラーゲン誘導血小板凝集阻害剤 |
US6589992B2 (en) | 1999-11-30 | 2003-07-08 | Parker Hughes Institute | Inhibiting collagen-induced platelet aggregation |
GB0005345D0 (en) * | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
AU2002236692A1 (en) * | 2000-10-23 | 2002-05-21 | Bristol-Myers Squibb Company | Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase, their identification and use |
WO2003016338A1 (en) * | 2001-08-15 | 2003-02-27 | Parker Hughes Institute | Crystal structure of the btk kinase domain |
AU2002360519B2 (en) * | 2001-12-07 | 2008-09-25 | University Of Wyoming | Methods and compositions for the diagnosis of asthma |
WO2004066994A1 (ja) * | 2003-01-28 | 2004-08-12 | Kansai Technology Licensing Organization Co. Ltd. | 抗癌剤 |
MX2007007330A (es) | 2004-12-16 | 2007-10-04 | Vertex Pharma | Piridonas de utilidad como inhibidores de quinasas . |
BRPI0621027A2 (pt) | 2006-01-13 | 2011-11-29 | Pharmacyclics Inc | composto, composição farmacêutica |
BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
US20120101113A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2009053269A1 (en) * | 2007-10-23 | 2009-04-30 | F. Hoffmann-La Roche Ag | Novel kinase inhibitors |
JP5479105B2 (ja) * | 2007-11-05 | 2014-04-23 | 国立大学法人佐賀大学 | 新規ユビキリン結合性小分子 |
US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
MX2011000661A (es) | 2008-07-16 | 2011-05-25 | Pharmacyclics Inc | Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos. |
IL300955A (en) | 2010-06-03 | 2023-04-01 | Pharmacyclics Llc | (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-H1-pyrazolo[4,3-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1- Indicated for use as a drug to treat chronic lymphocytic leukemia or small lymphocytic lymphoma |
AU2011282614B2 (en) | 2010-07-28 | 2015-11-26 | Janssen Pharmaceutica Nv | Methods of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors |
KR20140048968A (ko) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
UA114421C2 (uk) | 2012-06-04 | 2017-06-12 | Фармасайклікс Ллс | Кристалічна форма інгібітору тирозинкінази брутона |
CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
MX2015006168A (es) | 2012-11-15 | 2015-08-10 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas. |
CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
TWI649081B (zh) | 2013-08-02 | 2019-02-01 | 製藥公司 | 治療固態腫瘤之方法 |
US9415050B2 (en) | 2013-08-12 | 2016-08-16 | Pharmacyclics Llc | Methods for the treatment of HER2 amplified cancer |
MA38961A1 (fr) | 2013-09-30 | 2018-05-31 | Pharmacyclics Llc | Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose |
JP2016538270A (ja) | 2013-10-25 | 2016-12-08 | ファーマサイクリックス エルエルシー | 移植片対宿主病を処置し予防する方法 |
WO2015089481A2 (en) | 2013-12-13 | 2015-06-18 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
AU2014361798B2 (en) | 2013-12-13 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
CA2959602A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
BR112017002231A2 (pt) | 2014-08-07 | 2018-07-17 | Pharmacyclics Llc | novas formulações de um inibidor de tirosina cinase de bruton |
EP3715346B1 (de) | 2014-10-22 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Thiazolylhaltige verbindungen zur behandlung proliferativer erkrankungen |
SG11201707122QA (en) | 2015-03-03 | 2017-09-28 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibtor |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
WO1994014789A1 (en) | 1992-12-23 | 1994-07-07 | Smithkline Beecham Corporation | Coumarin derivatives as retroviral inhibitors |
US5489697A (en) | 1994-08-03 | 1996-02-06 | Medichem Research, Inc. | Method for the preparation of (+)-calanolide A and intermediates thereof |
EP1071658B1 (de) | 1998-04-17 | 2004-06-16 | Parker Hughes Institute | Btk inhibitoren und verfahren zur identifizierung und verwendung |
-
1999
- 1999-07-15 US US09/354,550 patent/US6306897B1/en not_active Expired - Fee Related
-
2000
- 2000-03-16 AU AU37480/00A patent/AU3748000A/en not_active Abandoned
- 2000-03-16 WO PCT/US2000/006805 patent/WO2000056737A2/en active IP Right Grant
- 2000-03-16 EP EP00916367A patent/EP1163243B1/de not_active Expired - Lifetime
- 2000-03-16 CA CA002365244A patent/CA2365244A1/en not_active Abandoned
- 2000-03-16 JP JP2000606598A patent/JP2003528801A/ja not_active Withdrawn
- 2000-03-16 AT AT00916367T patent/ATE256131T1/de not_active IP Right Cessation
- 2000-03-16 DE DE60007095T patent/DE60007095T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6306897B1 (en) | 2001-10-23 |
JP2003528801A (ja) | 2003-09-30 |
DE60007095T2 (de) | 2004-10-07 |
WO2000056737A2 (en) | 2000-09-28 |
EP1163243B1 (de) | 2003-12-10 |
WO2000056737A3 (en) | 2001-02-08 |
DE60007095D1 (de) | 2004-01-22 |
CA2365244A1 (en) | 2000-09-28 |
EP1163243A2 (de) | 2001-12-19 |
WO2000056737A9 (en) | 2001-10-25 |
AU3748000A (en) | 2000-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE256131T1 (de) | Calanolide zur hemmung von btk | |
ATE269295T1 (de) | Btk inhibitoren und verfahren zur identifizierung und verwendung | |
CY1105349T1 (el) | Θειαζολυλ-αναστολεις τυροκινασεων της οικογενειας tec | |
SE0301700D0 (sv) | Novel compounds | |
RS50660B (sr) | Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže | |
DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
TR200202194T2 (tr) | Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri | |
ATE455092T1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
EA200100773A1 (ru) | Замещенные 1-гетероциклические диариламины | |
EA200601555A1 (ru) | Замещенные индазол-о-глюкозиды | |
CA2366932A1 (en) | Cyclic protein tyrosine kinase inhibitors | |
CY1112687T1 (el) | Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες | |
ATE231872T1 (de) | Thiazolopyrimidinderivate | |
AR024138A1 (es) | Inhibidores de la proliferacion celular | |
TR200100054T2 (tr) | Paroksetin metansülfonat | |
BRPI0515721A (pt) | uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação | |
DE10082139T1 (de) | Zusammensetzung zur Behandlung von Reibungspaaren | |
DE502004002571D1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
ATE335481T1 (de) | Zolpidem hemitartrat solvat | |
BR0114903A (pt) | 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação | |
SE9904377D0 (sv) | Pharmaceutical combinations | |
SE9802937D0 (sv) | Novel compounds | |
SE0301650D0 (sv) | Novel compounds | |
DE602004032465D1 (de) | Referenzstandard zur charakterisierung von rosuvastatin | |
UY28685A1 (es) | Heterociclos con contenido de nitrógeno que afectan la transmisión sináptica glutamatérgica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |